Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES).
## Adult Dosing
* **Erosive esophagitis healing:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **Pathological hypersecretory conditions (e.g., ZES):** Initially 40 mg orally or intravenously twice daily. Doses may be increased as clinically indicated. Doses up to 240 mg intravenously once daily and up to 960 mg orally every 24 hours (divided into 4 doses) have been administered.
## Pediatric Dosing
* **Erosive esophagitis healing (ages 5 to 16 years):** 20 mg to 40 mg orally once daily for up to 8 weeks.
* Dosing for younger children or other indications in pediatrics is less established and requires careful consideration.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally once daily. No dose adjustment needed for renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of its formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Less Common: Rash, pruritus, elevated liver enzymes, bone fracture (with long-term use).
## Key Drug Interactions
* **Drugs requiring gastric pH for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, vitamin B12. Pantoprazole may decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider dose reduction or interruption of pantoprazole.
* **CYP2C19 substrates:** Clopidogrel. The clinical significance is uncertain, but some evidence suggests reduced clopidogrel efficacy.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., fatigue, muscle spasms, seizures, arrhythmias) with long-term use.
* Monitor for signs of C. difficile-associated diarrhea.
* Monitor bone mineral density with long-term use.
## Clinical Pearls
* Oral pantoprazole is generally preferred over IV when clinically feasible.
* For IV administration, reconstitute and dilute as per manufacturer instructions. Infusion rates vary.
* Long-term PPI use is associated with an increased risk of fractures, C. difficile infection, and hypomagnesemia. Consider the lowest effective dose for the shortest duration necessary.
* Pantoprazole 40 mg delayed-release tablets are typically administered 30-60 minutes before a meal.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for definitive patient care decisions.
